This model revealed CR duration >18 months (odds ratio (OR), 1.58; P=0.01), biallelic CEBPA mutation (OR, 2.15; P=0.04) and CBF-AML (OR, 2.20; P<0.001) as favorable variables and adverse cytogenetics (OR, 0.58; P=0.02) and FLT3-ITD (OR, 0.56, P=0.003) independent of allelic ratio as unfavorable variables. This evidence concerns the gene CEBPZ and acute myeloid leukemia.